ICU Admission: Clinical Trials

3 trials for ICU Admission, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 unknown. 1 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable1Completed 1
Phase 31Completed 1

Follow ICU Admission: new trials by email Literature Review of ICU Admission trials Research Report on ICU Admission

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PrognostICate- Study:Prognostication of ICU- and Ventilator- Days Over the Next Years Until 2040
Intensive Care Unit (ICU) treatment - ICU Admission
UnknownUniversity Hospital of Cologne100000002024-03-012024-07-23
Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial)
Nutraflora scFOS, Osmolite - Enteral Nutrition, Brain Injuries, Traumatic
Not applicableCompletedDuke University202017-10-232021-06-04
Pediatric Intensive Care Units (ICUs) at Emory-Children's Center Glycemic Control: The PedETrol Trial
Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring) - Pediatric Patient (1m-21y), ICU Admission
Phase 3CompletedIndiana University1532010-08-012015-08-31

Narrower conditions

Brain Injuries, Traumatic (1)  ·  Hyperglycemia (1)  ·  Hypoglycemia (1)  ·  Neurologic Manifestations (1)  ·  Wounds and Injuries (1)

Broader conditions

Brain Diseases (1)  ·  Brain Injuries (1)  ·  Central Nervous System Diseases (1)  ·  Craniocerebral Trauma (1)  ·  Glucose Metabolism Disorders (1)  ·  Metabolic Diseases (1)  ·  Nervous System Diseases (1)  ·  Nutritional and Metabolic Diseases (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)  ·  Trauma, Nervous System (1)

Interventions

Continuous Glucose Monitoring (1)  ·  Intensive Care Units (1)  ·  Osmolite (1)  ·  Therapeutics (1)

Sponsors

Duke University (1)  ·  Indiana University (1)  ·  University Hospital of Cologne (1)

Countries

United States (2)  ·  Germany (1)

Top investigators

Mark R Rigby, MD, PhD (1)  ·  Paul Wischmeyer, MD (1)

Results publications

PMID 41462238